Skip to main content
Clinical Trials/NCT03238586
NCT03238586
Completed
Not Applicable

HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions

Louisiana State University Health Sciences Center in New Orleans1 site in 1 country232 target enrollmentNovember 2012
ConditionsHIV/AIDS

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV/AIDS
Sponsor
Louisiana State University Health Sciences Center in New Orleans
Enrollment
232
Locations
1
Primary Endpoint
Viral load
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

A clinical study for patients with HIV that investigates the best way to reduce HIV transmission risk, and to improve the overall health of people living with HIV/AIDS. Participants will complete four assessments over the course of one year and will be randomly assigned to a five-week treatment program.

Detailed Description

The main purpose of this research study is to investigate the best way to reduce HIV transmission risk and to improve the overall health of people living with HIV/AIDS. This study tests an intervention program that aims to improve knowledge, motivation, and skills. The intervention program is designed to motivate participants to take their medications routinely, improve the quality of life for those living with HIV, and decrease risky behaviors that may lead to HIV transmission.

Registry
clinicaltrials.gov
Start Date
November 2012
End Date
August 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Patricia Molina

Richard Ashman, PhD Professor and Head Department of Physiology; Director Alcohol and Drug Abuse Center of Excellence

Louisiana State University Health Sciences Center in New Orleans

Eligibility Criteria

Inclusion Criteria

  • HIV positive
  • Recent alcohol use

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Viral load

Time Frame: Change from baseline at 3 months, 6 months and 1 year

The primary outcome measure will be disease progression or more specifically, the proportion of patients achieving viral suppression.

Study Sites (1)

Loading locations...

Similar Trials